Capital One analyst Zegbeh Jallah initiated coverage of Ideaya Biosciences with an Overweight rating and $29 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IDYA:
- Ideaya Biosciences to host virtual investor research and development day
- Ideaya Biosciences granted fast track designation for darovasertib
- Ideaya Biosciences announces Darrin Beaupre as chief medical officer
- IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update